Abdul Hussain Azizi

Abdul Hussain Azizi

Auto-generated profile, based on publicly available information

Abdul Hussain Azizi

Department of Cardiology (N.C., A.H.A.), Christiana Care Health System, Newark, DE

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in eClinicalMedicine
Verified
Journal Article
Open access
AAAbdul Hussain Azizi
Abdul Hussain Azizi
ISIrfan Shafi
Irfan Shafi
MZMatthew Zhao
Matthew Zhao
SCSaurav Chatterjee
Saurav Chatterjee
SRStephanie Clare Roth
Stephanie Clare Roth
RBRiyaz Bashir
Riyaz Bashir
Superior vena cava (SVC) syndrome is caused by the obstruction of the SVC and can result in significant morbidity and mortality. In contemporary practice, endovascular therapy (ET) has become the standard of care for a majority of these patients. This study is a systematic review and meta-analysis of the available literature to assess technical success, restenosis, and recurrence of SVC syndrome following endovascular intervention. For this meta-analysis, we conducted a systematic literature review of PubMed, Cochrane Library, and Embase databases from inception to April 14, 2021 for studies on ET for SVC syndrome. Studies included full-length journal articles on the use of ET among adults with SVC syndrome. Case reports or case series with fewer than 20 patients were excluded. We evaluated the endpoints of technical success rate, restenosis rate, and recurrence rates in SVC syndrome patients after endovascular stenting. The results of this study were calculated using random-effects models. We identified 6,012 reports, of which 39 studies met our inclusion criteria and were included for analysis. A total of 2200 patients received ET for SVC syndrome. The weighted technical success rate was 98.8% (95% CI 98.2–99.3) with low heterogeneity (I2=17.4%, p = 0.185), restenosis rate was 10.5% (95% CI 8.4–12.6) with moderate heterogeneity (I2=53.5%, p<0.001), and recurrence rate was 10.8% (95% CI 8.1–13.5) with high heterogeneity (I2=75.8%, p<0.001). Total complication rate was 8.6% (95% CI 7.3%-9.9%) with a mean complication rate of 7.5% (95% CI 4.7%-10.3%). Our systematic review revealed high technical success, low restenosis, and low recurrence rates following ET. Collectively, these results support the paradigm of ET as an effective and safe treatment for patients with SVC syndrome. None.

1 January 2021 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
AAAbdul Hussain Azizi
Abdul Hussain Azizi
ISIrfan Shafi
Irfan Shafi
MZMatthew Zhao
Matthew Zhao
SCSaurav Chatterjee
Saurav Chatterjee
SRStephanie Clare Roth
Stephanie Clare Roth
RBRiyaz Bashir
Riyaz Bashir
Objective: Superior vena cava (SVC) syndrome is caused by the obstruction of the SVC and can result in significant morbidity and mortality. In contemporary practice, endovascular therapy (ET) has become the standard of care for a majority of these patients. This study is a systematic review and meta-analysis of the available literature to assess the contemporary outcomes of SVC syndrome following endovascular intervention. Methods: For this meta-analysis, we conducted a systematic literature review of PubMed, Cochrane Library, and Embase databases from inception to September 25, 2020 for studies on ET for SVC syndrome. Studies included full-length journal articles on the use of ET among adults with SVC syndrome. Case reports or case series with fewer than 20 patients were excluded. We evaluated the endpoints of technical success rate, restenosis rate, and recurrence rates in SVC syndrome patients after endovascular stenting. The results of this study were calculated using random-effects models. Findings: We identified 5730 reports, of which 38 studies met our inclusion criteria and were included for analysis. A total of 2158 patients received ET for SVC syndrome. The weighted technical success rate was 98.9% (95% CI 98.3-99.4), restenosis rate was 10.6% (95% CI 8.5–12.8), and recurrence rate was 10.3% (95% CI 7.6–12.9). Complication rates were 7.35 ± 0.0786%. Interpretation Our systematic review revealed high technical success, low restenosis, and low recurrence rates following ET. Collectively, these results support the paradigm of ET as an effective and safe treatment for patients with SVC syndrome. Funding: None Declaration of Interest: Dr. Riyaz Bashir has an equity interest in Thrombolex Inc. All other authors have no competing interests to disclose.

1 September 2023 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
NLNicholas L. Luibil
Nicholas L. Luibil
NCNoor Chima
Noor Chima
AAAbdul H. Azizi
Abdul H. Azizi
CFCarly A. Fabrizio
Carly A. Fabrizio
MGMandip S. Gakhal
Mandip S. Gakhal